Nurix Therapeutics (NRIX) earnings
In the quarter ended May 2026, Nurix Therapeutics had revenue of $9M, down 79.5% on a year earlier, and diluted EPS of -0.81.
On October 8, 2026 it reported EPS of -1.03 against an estimate of -0.56 (missed).
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Last | Thu Oct 8, 2026 | — | -0.56 | -1.03 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Nurix Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| May 31, 2026 | $9M | -79.5% | -0.81 | — | -1041.7% | 2026-07-09 |
| Feb 28, 2026 | $6M | -66.1% | -0.79 | — | -1479.4% | 2026-04-08 |
| Nov 30, 2025 | $14M | +2.2% | — | — | -612.0% | 2026-01-28 |
| Aug 31, 2025 | $8M | -37.3% | -1.03 | — | -1157.7% | 2025-10-09 |
| May 31, 2025 | $44M | +264.3% | -0.52 | — | -109.7% | 2025-07-09 |
| Feb 28, 2025 | $18M | +11.3% | -0.67 | — | -340.7% | 2025-04-08 |
| Nov 30, 2024 | $13M | -12.4% | — | — | -486.7% | 2025-01-28 |
| Aug 31, 2024 | $13M | -31.8% | -0.67 | — | -433.8% | 2024-10-11 |
| May 31, 2024 | $12M | -60.6% | -0.71 | — | -401.4% | 2024-07-11 |
| Feb 29, 2024 | $17M | +30.7% | -0.76 | — | -272.6% | 2024-04-10 |
| Nov 30, 2023 | $15M | +123.5% | — | — | -299.1% | 2024-02-15 |
| Aug 31, 2023 | $18M | +71.1% | -0.68 | — | -216.7% | 2023-10-12 |
Questions
How did Nurix Therapeutics do last quarter?
In the quarter ended May 2026, Nurix Therapeutics had revenue of $9M, down 79.5% on a year earlier, and diluted EPS of -0.81.
From Nurix Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.